Design Therapeutics DSGN
NASDAQ DSGN
$10.65 -0.15 (-1.39%)
At close: Nov 10, 2026 · 4:00 PM EST

Design Therapeutics (DSGN) Long-Term Debt Repayments (2020)

Updated

Analysis

Design Therapeutics (DSGN) Long-Term Debt Repayments (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 1.00 Mn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 3.05 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 19.00 Mn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Design Therapeutics 678.89 Mn -179.78 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 400,000.00
API Access

Design Therapeutics Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=DSGN&period=max&api_key=YOUR_API_KEY